News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients
Nov 30, 2024, 16:08

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared on X:

“Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients: iScience

Authors: Rasmus Virenfeldt Flak, Emil Kofod-Olsen, Nikolaj Dich Sølvsten, Gintare Naujokaite, Ralf Agger, Mogens Tornby Stender, Signe Christensen, Susy Shim, Laurids Østergaard Poulsen, Sönke Detlefsen, Ole Thorlasius-Ussing, Morten Ladekar

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

When you combine one ineffective therapy in pancreatic cancer (aPD1) with another (IRE), the cumulative result is still ineffective. Everyone progressed right through it.”

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.

Anirban Maitra cancer Emil Kofod-Olsen Gintare Naujokaite Laurids Østergaard Poulsen Liver metastasis Mogens Tornby Stender Morten Ladekar Nikolaj Dich Sølvsten Ole Thorlasius-Ussing OncoDaily Oncology Pancreatic Cancer Ralf Agger Rasmus Virenfeldt Flak Signe Christensen Sönke Detlefsen Susy Shim
Special Coverage
Science
Dec 22, 2024, 10:15
Dégi László Csaba: Thrilled to announce the new Lancet Oncology Policy Review analyzing NCCPs worldwide
Science
Dec 22, 2024, 10:13
Denis Horgan: Delayed Access to Personalized Medicine in the EU - What’s the Cost to Patients?
Blog
Dec 22, 2024, 10:12
Emad Shash: Honor to be among the newly elected council of the Egyptian Cancer Society
Science
Dec 22, 2024, 10:03
María Natalia Gandur Quiroga: Checkpoint inhibitors and Fc functions - key findings in oncology immunotherapy
Science
Dec 22, 2024, 10:00
Francesco Maura: CD38 loss as mechanisms of resistance to anti-CD38 MoAb in myeloma
Science
Dec 22, 2024, 09:59
CDK4/6 inhibitors: mechanisms of resistance and where to find them - Lorenzo Gerratana
Blog
Dec 22, 2024, 09:53
India's Oncology Testing Market Projected to Grow at 2% CAGR Through 2033: GlobalData
Dialogues
Dec 22, 2024, 09:40
Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers
Dialogues
Dec 22, 2024, 09:04
Carlos Rodriguez-Galindo: The Man Who Will Cure the World
Science
Dec 22, 2024, 08:16
Essential Requirements for Quality Cancer Care: Ovarian - European Cancer Organisation
Science
Dec 22, 2024, 08:13
Liang Cheng: Advancements in biomarkers and molecular diagnostics in HR+ Breast Cancer
Science
Dec 22, 2024, 07:59
Ilana Schlam: The BRIDGES study is out